Contingent Consideration - Additional Information (Detail)			3 Months Ended	12 Months Ended
	Nov. 03, 2020 USD ($) $ / shares shares	Jul. 12, 2019 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) Milestone	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Business Acquisition [Line Items]
Contingent consideration liability (see Note 8)			$ 5,390,000	$ 6,090,000	$ 5,390,000	$ 2,750,000
Change in value of contingent consideration for acquired in-process research and development				$ 700,000	$ 16,265,010
Regulatory milestone achieved | Milestone				0
Contingent consideration				$ 6,090,000
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Up-front consideration	$ 13,600,000
Shares issued for contingent milestone payment | shares	1,694,906
Period for submission of clinical trial notification	60 days
Submission date of clinical trial notification	Oct. 29, 2020
Regulatory Milestones [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Change in value of contingent consideration for acquired in-process research and development			$ 5,400,000
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date		Jul. 08, 2019
Unregistered shares of common stock | shares		1,887,250
Up-front consideration		$ 5,000,000.0
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Consideration amount | $ / shares	$ 9.57
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Contingent consideration liability (see Note 8)		$ 5,000,000.0
Estimated future contingent consideration term		60 days
Number of consecutive trading days		20 days
Consideration amount | $ / shares		$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Contingent consideration liability (see Note 8)		$ 3,000,000.0
Estimated future contingent consideration term		60 days
Number of consecutive trading days		20 days
Consideration amount | $ / shares		$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Contingent consideration liability (see Note 8)		$ 80,000,000.0
License agreement term		10 years
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Upfront consideration release at 3 months		50.00%
Upfront consideration release at 9 months		50.00%
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Contingent consideration liability (see Note 8)		$ 88,000,000.0